NTLA241220P22500
- 8.20
- 0.000.00%
Intellia Therapeutics Newsroom
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $40
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $60 to $90
Positive Buy Rating for Intellia Therapeutics Amid Promising Trial Results for Nex-z in ATTR-CM
Intellia Therapeutics Is Maintained at Overweight by Wells Fargo
Intellia Therapeutics Price Target Maintained With a $14.00/Share by Wedbush
Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $91
Intellia Therapeutics Analyst Ratings
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $40
CCORF Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $90
Morgan Stanley Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $56
Truist Financial Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Announces Target Price $90
Intellia Therapeutics (NTLA) Gets a Buy From Truist Financial
Oppenheimer Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $60
Truist Securities Cuts Price Target on Intellia Therapeutics to $90 From $120, Maintains Buy Rating
Analysts Are Bullish on These Healthcare Stocks: Cullinan Management (CGEM), Intellia Therapeutics (NTLA)
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Veeva Systems (VEEV) and Neuren Pharmaceuticals Limited (OtherNURPF)
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $45 to $60
Intellia Therapeutics Is Maintained at Overweight by Barclays
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $40 to $88
Intellia Therapeutics: Promising Pipeline and Financial Stability Drive Buy Rating